Skip to main navigation
Skip to search
Skip to main content
University of Johannesburg Home
Home
Scholars
Research entities
Research output
Press/Media
Equipment & facilities
Prestigious awards
Search by expertise, name or affiliation
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian
, Amirhossein Sheida
, Mohammad Taghizadieh
, Mohammad Yousef Memar
,
Michael R. Hamblin
, Hossein Bannazadeh Baghi
, Javid Sadri Nahand
, Zatollah Asemi
, Hamed Mirzaei
Laser Research Centre
Shahid Beheshti University of Medical Sciences
Kashan University of Medical Sciences and Health Services
Tabriz University of Medical Sciences
Research output
:
Contribution to journal
›
Review article
›
peer-review
128
Citations (Scopus)
Overview
Fingerprint
Press/Media
(1)
Fingerprint
Dive into the research topics of 'Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Ritonavir
100%
Nirmatrelvir
100%
Proteinase
57%
Severe Acute Respiratory Syndrome Coronavirus 2
57%
Antivirus Agent
28%
Coronavirinae
14%
Side Effect
14%
Infection
14%
Protein Processing
14%
Human Immunodeficiency Virus Proteinase Inhibitor
14%
Virus Genome
14%
Cytochrome P450 Family 3
14%
Antiviral Activity
14%
Enhancer Region
14%
COVID-19
14%
Pharmacology, Toxicology and Pharmaceutical Science
Nirmatrelvir
100%
Ritonavir
100%
SARS Coronavirus
57%
Proteinase
57%
Antivirus Agent
28%
Antiviral Activity
14%
Side Effect
14%
Infection
14%
Coronavirinae
14%
Pandemic
14%
Human Immunodeficiency Virus Proteinase Inhibitor
14%
Cytochrome P450 Family 3
14%
Keyphrases
Nirmatrelvir
100%
Paxlovid
100%
Protease
57%
Ritonavir
42%
SARS-CoV-2 nucleocapsid Protein
14%
Promising Target
14%
Unanswered Questions
14%
Metabolic Enzymes
14%
Coronavirus Variants
14%
Cytochrome P450 (CYP450)
14%
Protein Processing
14%
HIV Protease Inhibitors
14%
SARS-CoV-2 Infection
14%